Hicks, Elizabeth Daly http://orcid.org/0000-0002-0832-1648
Hall, Geoffrey http://orcid.org/0000-0002-1071-4328
Hershfield, Michael S. http://orcid.org/0000-0003-3589-8554
Tarrant, Teresa K. http://orcid.org/0000-0003-4067-5363
Bali, Pawan
Sleasman, John W. http://orcid.org/0000-0003-0078-5867
Buckley, Rebecca H. http://orcid.org/0000-0002-6914-346X
Mousallem, Talal http://orcid.org/0000-0002-3692-8930
Funding for this research was provided by:
NIH T32 Training Grant (T32AI007062, T32AI007062)
The Jeffrey Modell Foundation
Article History
Received: 5 January 2024
Accepted: 11 April 2024
First Online: 27 April 2024
Declarations
:
: The legal representatives for all participants provided written consent for <i>enrollment into protocol, Genetic and Functional Analysis of Primary Immune Deficiencies (</i>Pro00066839) which was approved by the institutional review board of Duke University
: Dr. Mousallem received funding from Chiesi USA for a project entitled: A Single Arm, Open-Label, Multicenter, Registry Study of Revcovi Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy. Dr. Mousallem is the Duke Site PI for PIDTC (NIAID-University of California, San Francisco U54 AI082973 Puck (PI) 09/2019-08/2024) - Prospective Study of SCID Infants who receive Hematopoietic Cell Therapy. Dr. Sleasman receives grant support from Sumitomo Pharma. Dr. Tarrant receives funding from Chiesi USA for a project entitled: Diagnosis of purine immune deficiencies and monitoring of adenosine deaminase replacement therapy. Dr. Tarrant also receives grant support from Amgen and X4 Pharmaceuticals. Dr. Hershfield receives funding from Chiesi USA for a project entitled: Diagnosis of purine immune deficiencies and monitoring of adenosine deaminase replacement therapy. Drs. Mousallem and Tarrant served on the advisory board for Chiesi USA, 2023.